Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Puma Biotechnology (PBYI) Income from Continuing Operations (2017 - 2025)

Puma Biotechnology's Income from Continuing Operations history spans 9 years, with the latest figure at 17673000.0 for Q4 2025.

  • For Q4 2025, Income from Continuing Operations fell 236.45% year-over-year to 17673000.0; the TTM value through Sep 2025 reached 30625000.0, up 31.77%, while the annual FY2024 figure was 23925000.0, 10.81% up from the prior year.
  • Income from Continuing Operations reached 17673000.0 in Q4 2025 per PBYI's latest filing, down from 8844000.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 20317000.0 in Q3 2024 to a low of 44672000.0 in Q3 2021.
  • Average Income from Continuing Operations over 5 years is 824500.0, with a median of 2550000.0 recorded in 2023.
  • Peak YoY movement for Income from Continuing Operations: soared 1710.0% in 2023, then plummeted 443.68% in 2024.
  • A 5-year view of Income from Continuing Operations shows it stood at 4224000.0 in 2021, then plummeted by 232.77% to 5608000.0 in 2022, then skyrocketed by 318.76% to 12268000.0 in 2023, then rose by 5.58% to 12952000.0 in 2024, then tumbled by 236.45% to 17673000.0 in 2025.
  • Per Business Quant, the three most recent readings for PBYI's Income from Continuing Operations are 17673000.0 (Q4 2025), 8844000.0 (Q3 2025), and 5855000.0 (Q2 2025).